Hydroxychloroquine and systemic lupus: a reappraisal

被引:8
作者
Costedoat-Chalumeau, N. [1 ]
Leroux, G. [1 ]
Amoura, Z. [1 ]
Piette, J. -C. [1 ]
机构
[1] Univ Paris 06, CHU Pitie Salpetriere, Serv Med Interne, AP HP,Ctr Reference Natl Lupus & Syndrome Antipho, F-75651 Paris 13, France
来源
REVUE DE MEDECINE INTERNE | 2008年 / 29卷 / 09期
关键词
hydroxychloroquine; systemic lupus erythematosus; therapeutic drug monitoring; drug dosage;
D O I
10.1016/j.revmed.2007.05.031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose. - Hydroxychloroquine (HCQ) is still too often considered as a second-line treatment in systemic lupus erythematosus (SLE) patients. Key points. - Recently, interest for this drug has grown as a consequence of its favorable efficacy/toxicity ratio, its low cost and the availability of a blood measurement assay. Its efficiency has been demonstrated in the reduction of the risk of SLE flares and of overall damage accrual. The properties of HCQ also include a beneficial effect on lipid profile, and a protective effect against the occurrence of thrombotic events and of low bone mineral density related to corticosteroids. As a consequence, HCQ appears to have a protective effect on survival in people with SLE. Side-effects and contraindications are rare. Even if the incidence of retinopathy in clinical practice is very low, regular screening of this complication is required, but its modalities are not consensual. Conclusion. - These data are strong evidence for a wide prescription of HCQ. This should easily improve the management of our SLE patients. (C) 2007 Elsevier Masson SAS. Tons droits reserves.
引用
收藏
页码:735 / 737
页数:3
相关论文
共 40 条
[11]  
ESDAILE J, 1991, NEW ENGL J MED, V324, P150
[12]   Systemic lupus erythematosus in three ethnic groups -: XVI.: Association of hydroxychloroquine use with reduced risk of damage accrual [J].
Fessler, BJ ;
Alarcón, GS ;
McGwin, G ;
Roseman, J ;
Bastian, HM ;
Friedman, AW ;
Baethge, BA ;
Vilá, L ;
Reveille, JD .
ARTHRITIS AND RHEUMATISM, 2005, 52 (05) :1473-1480
[13]   Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis [J].
Ginzler, EM ;
Dooley, MA ;
Aranow, C ;
Kim, MY ;
Buyon, J ;
Merrill, JT ;
Petri, M ;
Gilkeson, GS ;
Wallace, DJ ;
Weisman, MH ;
Appel, GB .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) :2219-2228
[14]  
HODIS HN, 1993, J RHEUMATOL, V20, P661
[15]   Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents [J].
Karim, MY ;
Alba, P ;
Cuadrado, MJ ;
Abbs, IC ;
D'Cruz, DP ;
Khamashta, MA ;
Hughes, GRV .
RHEUMATOLOGY, 2002, 41 (08) :876-882
[16]   Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis [J].
Kasitanon, N. ;
Fine, D. M. ;
Haas, M. ;
Magder, L. S. ;
Petri, M. .
LUPUS, 2006, 15 (06) :366-370
[17]  
Lakshminarayanan S, 2001, J RHEUMATOL, V28, P102
[18]   Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice [J].
Levy, GD ;
Munz, SJ ;
Paschal, J ;
Cohen, HB ;
Pince, KJ ;
Peterson, T .
ARTHRITIS AND RHEUMATISM, 1997, 40 (08) :1482-1486
[19]   The dilemma of hydroxychloroquine screening: New information from the multifocal ERG [J].
Marmor, MF .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2005, 140 (05) :894-895
[20]   New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy [J].
Marmor, MF .
ARTHRITIS AND RHEUMATISM, 2003, 48 (06) :1764-1764